ZED1227 prevents increased mucosal injury in celiac disease

ZED1227 prevents increased mucosal injury in celiac disease

Transglutaminase 2 inhibitor ZED1227 decreased intestinal mucosal injury among patients with celiac disease, according to research published in The New England Journal of Medicine.“The only available treatment for celiac disease is lifelong adherence to a strict gluten-free diet, a diet that is difficult to maintain. … Moreover, many patients with celiac disease report having persistent symptoms despite adherence to the gluten-free diet. Thus, there is an unmet medical need for an effective treatment adjunct to a strict gluten-free diet,” Detlef Schuppan, MD, PhD, JohannesRead More

Share on facebook
Share on twitter
Share on linkedin